Mercia Technologies. Good progress across the portfolio. 17.7% growth in direct investment portfolio. Commercial traction in key companies

Similar documents
InMed Pharmaceuticals

JackpotJoy plc. A transformational year. Revenue and EBITDA slightly ahead of estimates. Strong operating cash flow dividends from 2019

TerraNet Holding. Irons in the fire. Five new strategic development orders won in Q317. Cash flow burn reflecting multi-project activity

TXT e-solutions. Steady growth in Q3. Growth for both businesses in Q3. Outlook and changes to forecasts

K3 Business Technology

Paysafe Group. Growth normalises. Growth moderates in H117. Pro forma financials show potential impact of deals

OTC Markets Group. Record quarterly revenues. Q115 Corporate services revenue rises 54% Operating expenses rise 18% in Q115.

Centrale del Latte d'italia

TXT e-solutions. Strong cash flow supports dividend boost. PACE acquisition boosts FY16 performance. Minor changes to earnings forecasts

Mondo TV. YooHoo! Netflix deal drives significant upgrades. Global deal with Netflix, new Chinese productions. Significant increase to five-year plan

Shanks Group. Global commodity crisis offsetting progress. Netherlands Commercial progress encouraging

Centrale del Latte d'italia

Eddie Stobart Logistics

Monitise. FY14 growth on track. Focus on expanding the network. Guidance maintained for FY14. Valuation: Reflects growth potential.

ReNeuron Group. US exclusivity deal - more than non-dilutive cash. FY18 results: Strong cash balance. Funded for a busy programme

Gear4music Holdings. Market share gains and margin boost. Strong pre-christmas trading. FY18 forecast maintained

GB Group. PCA acquisition an excellent fit. PCA adds SME reach to address intelligence services. Earnings enhancing despite growth investment

International Stem Cell

Evolva. EverSweet. Delivering on the new strategy. FY17 results. Valuation: Fair value of CHF0.60 per share. FY17 results.

XP Power. Strong demand drives record performance in H1. H118 sees continuation of strong growth

Carr s Group. Diversification continues to give resilience. PBT up for H117 as UK farmers gain in confidence

Centrale del Latte d'italia

K3 Business Technology

Sealegs Corporation. Sea change. H1 update. Changing business mix. Valuation: New focus improves valuation. H1 results

Quixant. A very promising year ahead. Volume deliveries to new major customers. Current order book over double the prior year

Piteco. Bold entry into the US marketplace. Acquisition of US payments software provider. Forecasts: FY18 revenues rise by 34%, EPS by 12%

KEFI Minerals. Counting down to production. Outstanding matters. Valuation: 6.55p/sh in FY18 rising to 7.21p/sh in FY19.

Antofagasta. Q3 production and costs better than forecast. Q313 production ahead of forecast. FY13 EPS forecast upgraded

GLG Life Tech. Luo Han Guo drives revenue growth. Tate & Lyle LHG contract boosts top line. H3 and H4 leaf should improve stevia margins

Progress in a backward market

Avalon Rare Metals. Refining Nechalacho s future. Nechalacho changing shape significantly. Agreement with Northwest Territory Métis Nation

Circle Property. Lifting estimates again. Revaluation gains and strong rent growth. Upside potential from refurbished assets

GFT Group. IT services pure-play focused on banks. Disposal of emagine. Acquisition of Adesis Netlife SL. Forecasts: Adjusted for effects of the deals

artnet For art's sake FY15: Art fair partnerships and forays to China Intended reporting change Valuation: Overshadowed Q1 figures

Regional REIT. Asset growth and refinancing completed. Further portfolio growth and diversification. Acquisition benefit offset by underlying revision

The Quarto Group. Good visibility into H2. Building on strengths. Group in improving shape for CFO transition. Valuation: Discount remains substantial

Ubisense. Geographic expansion. Ubisense acquires Asian partner. Expanding the opportunity in Asia. Changes to forecasts

Carclo. All going to plan. TP benefiting from expansion to support customers. FLTC acquisition supports further Wipac growth

Medserv. Pieces fitting into place H118. On track to deliver growth. Valuation: Backlog underpins uplift. H118 results. Industrial support services

Tourism Holdings. ROCE exceeds 14% long-term target. Key drivers remain positive. Deeper customer relationships to drive yield

Regional REIT. Retail eligible bond 4.5% Regional markets have remained robust. Retail eligible bond offering. Launch of bond issue.

High-impact exploration offshore Philippines

Expert System. Building the foundations for growth. Contract wins delayed by integration efforts. Company confident that outlook remains positive

Cooks Global Foods. Focused on capital requirements results restated. CGF budgets for 650 stores, targets 800 by 2021

Global Bioenergies. String of successes and new financing. Forecasts updated to reflect results & new financing

LPE sector performance

Carclo. Contract delays to affect H218 performance. Delayed placement of contracts by customers. Non-medical demand lower than forecast.

Ceres Power Holdings. Progressing towards commercialisation. Progressing the technology. Securing routes to market

Mondo TV. Guidance raised for full year. H117 highlights: Strong licensing sales. Outlook: Net profit guidance raised

Sigma Capital Group. New funding structure to finance project growth. JV to deliver initial 200m portfolio of 2,000 homes.

Aberdeen Asset Management

WANdisco. Cloud OEM agreement with Virtustream/Dell. Second OEM, first for cloud. Cloud credentials strengthened

Pura Vida Energy. Reaction to drilling. Sharp sell-off on no news. Results expected no earlier than late July. Increased stock volatility not unusual

SNP Schneider-Neureither & Partner

ADVA Optical Networking FY12 results

Polypipe Group. Strong Residential performance. Sector themes maintained, some portfolio tweaks. French disposal modestly dilutive to earnings

Ceres Power Holdings. Strengthening customer engagement. Customer engagement intensifying. Engagement underpinned by technology advances

Athersys. Progress on all fronts. Timeline for FDA approval accelerated. mrs shift analysis is primary endpoint. Moving forward in Japan

Helma Eigenheimbau. Scale research report - Update. Market bottlenecks limiting momentum. H117 results showing moderate growth

Bionomics. PTSD programme on track for results in Q3. PTSD treatment complete, results coming. Agitation study ongoing

China Water Affairs Group

Evolva. A cloudier picture. Production update agreement not yet reached. FY16 revenue lower than previously expected

Cooks Global Foods. Funded for growth. Growth plans. Interim results. Valuation: Upside in valuation. Interim results.

NAHL Group. Maiden interims show strong profit growth. Significant rise in margins in H114. FY14e and FY15e PBT and EPS estimates raised

Tungsten Corporation. Focusing on growth and efficiency. AGM update. Outlook. Valuation. Company update. Financial services

Carr's Group. Profits dip as expected with FY18 recovery underway. FY17 impacted by external factors. FY18 recovery underway

Deutsche Beteiligungs

PPHE Hotel Group. More of the same. Continued outperformance. Favourable asset management climate. Valuation: Closing the discount to NAV

Caledonia Mining. Production in line, EPS down on macro factors. Record quarterly production. New (lower) gold price forecasts

Picton Property Income

EMIS Group. Unveiling EMIS-X. Plan to unify all solutions on EMIS-X platform. Capitalising on strong market positions

paragon Accelerating progress Q2 displays accelerating performance Guidance changes reflect growth initiatives Valuation: Rating not reflecting growth

Record. Maintaining client commitment. FY18 result. Outlook: Seeing well-diversified interest. Valuation. FY18 results. Financial services

Rockhopper Exploration

AFH Financial Group. Delivering on acquisitions and organic growth. FY15 results: Beating expectations on organic growth

Thin Film Electronics

Kongsberg Automotive investment headwind, but technology wins results affected by investment, but progress

Boku. Strong H1 supports future growth. Strong volume growth continues in H118. Investing for sustained growth. Valuation: Premium for growth

S&U. Positioning for sustainable growth. H119 results. Adapting to market background. Valuation: Maintained on slightly lower estimates.

German Startups Group

K3 Business Technology Update on preliminary results

Park Group. Continued growth in earnings and cash. Small forecast increase, awaiting IFRS 15. New management team takes up the baton

TransContainer. Russian rail volumes continue to grow. Story intact: Runaway market growth. EBITDA growth set to continue

SITO Mobile. A strong end to a transformational year. Transformational year ends on a high note. Pipeline looks promising

The Quarto Group. 40 years young. Children s list delivers on promise. Investing in new titles, building IP for future sales

Bellus Health. Thallion deal likely as Jaguar backs revised CVRs. CVR revisions mostly modest; Jaguar supports bid

Athersys. On track for a big Japanese trial. Japanese stroke trial design. Larger trial has multiple benefits

Vectron Systems. Scale research report - Update. Evolving the business. Boost from regulatory changes recedes. Increased focus on cloud services

Entertainment One. PJ Masks catching Peppa. Strong growth in profitability. PJ Masks joins Peppa as a global Family brand

Photocure. Nordic sales bounce back. Eight more blue light cystoscopy units placed in US. Hexvix/Cysview added to bladder cancer guidelines

PDL BioPharma. An update on several fronts. Valeant has not been reporting or paying on time. Auvi-Q recalled, but there is an interest reserve

Game Digital. Not a game changer. Early days in the strategic transition. Trading update: Short-term timing delays

Tungsten Corporation. Focus on delivery and growth. Full year 2017 results demonstrate progress. Outlook. Valuation. FY17 results. Financial services

Oxford BioMedica. Orchard deal adds to growing revenue stream. Orchard Therapeutics deal adds to growing list

Astex Pharmaceuticals

DeA Capital. Expanding asset management platform. AUM growth accelerates in Q4. A healthy net investment balance supports dividends

Pantaflix. Scale research report Update. Name change reflects VOD strategy. Progressing its VOD strategy. Overview of H117 results

RNTS Media. Scaling up with acquisitions. Mediation platform very well received. Product launches - growth should pick up in H2

TransGlobe Energy. EGPC receivables issue resolved. EGPC makes significant receivables reduction. Focus in Egypt shifts from seismic to drilling

Intec Pharma. Phase III more than half the way there. Gastroscopy substudy complete. New pharmacokinetic study on deck. New plan for AP cannabinoids

Transcription:

Mercia Technologies Good progress across the portfolio H119 results Investment companies Mercia s H119 results reflected continued steady progress across the portfolio, with net assets rising slightly to 125.2m and FuM remaining stable at 394.9m. The direct investment portfolio increased 17.7% to 77.8m, reflecting 9.2m of cash investment as well as 2.6m fair value uplift. Key portfolio companies continue to deliver against commercial milestones and with c 60m of investment expected in FY19, Mercia is well positioned for further progress in FY19. The shares continue to trade at a significant discount to NAV (0.74x) and peer group comparators. 4 December 2018 Price 30.5p Market cap 93m Net cash ( m) at 30 September 2018 38.3 Shares in issue 303.3m Free float 23.2% Net cash* Direct FuM NAV NAV per P/NAV Year end ( m) investments ( m) ( m) ( m) share (p) (x) 03/16 30.9 38.1 220.0 80.0 26.3 1.16 03/17 59.6 52.0 336.5 121.4 40.0 0.76 03/18 49.4 66.1 400.0 123.5 40.7 0.75 H119 38.3 77.8 394.9 125.2 41.3 0.74 Note: *Includes liquid securities but not funds held on behalf of EIS investors. Code Primary exchange Secondary exchange Share price performance MERC AIM N/A 17.7% growth in direct investment portfolio Mercia reported H119 net assets of 125.2m, which compares to 123.5m at FY18. As a result of a 9.2m of investment and 2.6m fair value uplift, the direct investment portfolio grew to 77.8m from 66.0m at FY18. Within the Mercia Fund Managers (MFM) subsidiary, FuM remained steady at 394.9m (vs c 400m at FY18). Importantly, MFM also contributed the majority of 5.27m revenues at H119 (vs 4.85m in H118), with a 19.1% reduction in operating expenses to 0.69m vs the comparable period ( 0.85m for H118). Mercia continues to expect to invest c 60m during FY19, of which 20-25m will be direct balance sheet investments. Commercial traction in key companies Within the 77.8m direct investment portfolio, four companies comprise 44% of the value, reporting significant commercial milestones during the period, including multi-million pound contracts for Oxford Genetics and ndreams. Warwick Acoustics received further funding from Mercia and Intechnica saw a 16.3% uplift in value. Also notable in the direct portfolio, Aston EyeTech signed a multi-million pound contract, while VirtTrade signed partnership agreements with both Formula 1 and Valiant Comics. Please see our October initiation for more information on the key portfolio businesses. Valuation: 0.74x NAV, does not include MFM Mercia s shares trade at a meaningful discount to NAV (0.74x). This compares to its peers such as IP Group at 0.83x and Draper Esprit at 1.19x. We note that the simple NAV calculation does not include profits generated from the MFM business, which we estimate at a value of c 9p per share, which is unchanged from the initiation (bringing the total discount to NAV to 0.60x). Catalysts for a re-rating would include meaningful commercialisation of the direct investments and/or further successful exits. % 1m 3m 12m Abs (2.9) (1.0) (11.6) Rel (local) (1.8) 6.1 (8.0) 52-week high/low 43.5p 27.5p Business description Mercia Technologies is a leading player in the funding and scaling of high-growth businesses. Through its subsidiary managed funds (MFM) and its own balance sheet, Mercia provides a complete capital solution to UK SMEs, with a focus on the Midlands and North UK. Next event 2019 preliminary results July 2019 Analysts Victoria Pease +44 (0)20 3077 5700 Richard Williamson +44 (0)20 3077 5700 tech@edisongroup.com Edison profile page Mercia Technologies is a research client of Edison Investment Research Limited

Investment summary Stable net assets and FuM Mercia reported a net asset value of 125.2m at H119 (vs 123.5m at FY18), which equates to 41.3p per share. Largely as a result of a 9.2m direct investment, unrestricted cash and short-term liquidity investments fell from 49.4m at FY18 to 38.3m at H119. This is in line with expectations and management anticipates total direct investment of 20-25m for FY19. The MFM subsidiary business reported FuM of 394.9m, which is in line with c 400m at FY18. The funds have 216m available capital to invest and MFM is currently investing c 25m pa from its venture funds. The aim is to create a healthy pipeline of investments, before making selective new direct balance sheet investments so-called, Emerging Stars. Group revenues increased by 8.7% to 5.3m and included 3.6m fund management fees, 0.5m initial management fees and 1.1m portfolio director fees. Accounting for the increased fee income, net expenses reduced to 0.7m ( 0.9m at H118). The contribution from the MFM business is a key differentiator for Mercia, as central costs are minimised and balance sheet cash is largely directed towards growing the direct investment portfolio. Direct investment portfolio up 17.7% vs prior year. Mercia s direct investment portfolio grew from 66.0m at FY18 to 77.8m at H119, with the value increasing due to 9.2m of investment, as well as a 2.6m net fair value increase. 3.2m fair value gains resulted from uplifts for Faradion and Intechnica, based upon thirdparty indications of market value, an uplift at Voxpopme following a successful syndicated third-party investment round and an uplift at The Native Antigen Company as its profitable trading progresses. 0.6m downward fair value movement: This reflects a 0.5m reduction in Concepta s share price, as well as a 0.1m reduction in a small direct investment, where Mercia elected not to provide further funding. In total, 10% of the portfolio has been subject to impairments. Edge Case Games sold post period end: following a disappointing relaunch of its title Fractured Space during the summer, Edge Case Games was sold in an asset and royalty deal to Wargaming. Over 1.0m was returned to Mercia up-front, with deferred consideration of up to $10m possible over time. Two new Emerging Stars brought across from MFM: Mercia has invested 0.5m into Locate Bio (regenerative medicine) and 2.0m into W2 Global Data Solutions (W2 was post period end). Similar to previous reporting periods, Mercia s top 20 direct investments represented 98.7% of total portfolio value (includes Edge Case Games, excludes W2 Global Data Solutions and Locate Bio). Milestones achieved Significant commercial milestones achieved by direct investment portfolio companies include: Oxford Genetics won its largest multi-million pound contract to date with a global e-commerce provider of reagents and tools to the research and clinical community. ndreams won its largest multi-million pound contract to date with a high-profile global technology company. Aston EyeTech (trading as Eyoto) won its largest multi-million pound contract to date with one of the fastest growing optical retailers in the world. Mercia Technologies 4 December 2018 2

VirtTrade signed partnership agreements with both Formula 1 and Valiant Comics to develop digital collectibles content. Exhibit 1: Direct investment portfolio Please see our note, Realising value for more information on the key portfolio businesses. ( '000) Sector Net value 1/4/18 Net cash invested in H119 Fair value change H119 Net value 30/9/18 % held at 30/9/18 ndreams Ltd Digital/digital entertainment 12,979 - - 12,979 45.6 Oxford Genetics Ltd Life sciences/biosciences 9,090 - - 9,090 40.5 Warwick Acoustics Ltd EMME 6,152 1,000-7,152 64 Intechnica Ltd Software and the internet 4,021-656 4,677 27.9 Impression Technologies Ltd EMME 3,107 1,500-4,607 31.4 Ton UK Ltd t/a Intelligent Positioning Software and the internet 4,216 - - 4,216 28.8 Faradion Ltd EMME 1,299 600 1,625 3,524 18.1 Medherant Ltd Life sciences/biosciences 3,453 - - 3,453 31.9 Smart Antenna Technologies Ltd EMME 2,148 1,200-3,348 32.2 Edge Case Games Ltd Digital/digital entertainment 2,000 1,150-3,150 21.2 VirtTrade Ltd Digital/digital entertainment 2,538 550-3,088 28.4 Voxpopme Ltd Software and the internet 1,000 1,500 526 3,026 21.8 PsiOxus Therapeutics Ltd Life Sciences/biosciences 2,377 - - 2,377 1.5 The Native Antigen Company Ltd Life sciences/biosciences 1,942-382 2,324 32.7 LM Technologies Ltd EMME 1,913 - - 1,913 41.4 surecore Ltd EMME 1,500 334-1,834 24.4 Aston EyeTech Ltd t/a Eyoto Life sciences/biosciences 1,750 - - 1,750 18.7 Crowd Reactive Ltd Software and the internet 1,650 (13) - 1,637 26.2 Soccer Manager Ltd Digital/digital entertainment 1,199 300-1,499 31.6 Concepta Plc Life sciences/biosciences 1,306 365-468 1,203 18.2 Other direct investments - 430 670-120 980 n/a Total 66,070 9,156 2,601 77,827 n/a Source: Mercia Technologies: Note. EMME is Electronics, Materials, Manufacturing and Engineering Mercia Technologies 4 December 2018 3

Exhibit 2: Financial summary '000 2014 2015 2016 2017 2018 31-March IFRS IFRS IFRS IFRS IFRS INCOME STATEMENT Revenue 723 508 1,755 6,660 10,197 Cost of Sales (26) (10) (79) (92) 0 Gross Profit 697 498 1,676 6,568 10,197 Operating Profit (before amort. and except.) 42 2,937 (1,439) 2,624 3,258 Amortisation of acquired intangibles 0 0 (17) (301) (301) Fair value changes 0 3,934 896 4,268 2,823 Realised gains 0 0 839 871 Exceptionals 0 (1,018) (372) (1,125) (1,125) Share-based payments 0 (44) (230) (395) (497) Reported operating profit 42 1,875 (2,058) 803 1,335 Net Interest 0 93 361 186 274 Joint ventures & associates (post tax) 0 0 0 0 0 Profit Before Tax (norm) 42 3,030 (1,078) 2,810 3,532 Profit Before Tax (reported) 42 1,968 (1,697) 989 1,609 Reported tax 0 0 0 54 54 Profit After Tax (norm) 42 3,030 (1,078) 2,810 3,532 Profit After Tax (reported) 42 1,968 (1,697) 1,043 1,663 Minority interests 0 0 0 0 0 Discontinued operations 0 0 0 0 0 Net income (normalised) 42 3,030 (1,078) 2,810 3,532 Net income (reported) 42 1,968 (1,697) 1,043 1,663 Average Number of Shares Outstanding (m) 13 212 212 224 301 EPS - normalised (p) 0.33 1.43 (0.51) 1.26 1.17 EPS - diluted normalised (p) 0.33 1.43 (0.51) 1.26 1.17 EPS - basic reported (p) 0.33 0.93 (0.80) 0.47 0.55 Dividend (p) 0.00 0.00 0.00 0.00 0.00 Revenue growth (%) N/A (-29.7) 245.5 279.5 53.1 Gross Margin (%) 96.4 98.0 95.5 98.6 100.0 Normalised Operating Margin 5.8 578.1-82.0 39.4 32.0 BALANCE SHEET Fixed Assets 27 27,121 50,103 63,693 77,428 Intangible Assets 0 2,455 11,815 11,514 11,213 Tangible Assets 27 49 145 151 145 Investments & other 0 24,617 38,143 52,028 66,070 Current Assets 223 54,349 31,730 64,576 53,965 Stocks 0 0 0 0 0 Debtors 184 716 798 747 1,057 Cash & cash equivalents 39 23,633 20,932 28,829 42,908 Short term liquidity investments 0 30,000 10,000 35,000 10,000 Current Liabilities (141) (631) (1,521) (6,698) (7,760) Creditors (141) (631) (1,521) (6,698) (7,760) Tax and social security 0 0 0 0 0 Short term borrowings 0 0 0 0 0 Other 0 0 0 0 0 Long Term Liabilities 0 0 (271) (217) (163) Long term borrowings 0 0 0 0 0 Other long term liabilities 0 0 (271) (217) (163) Net Assets 108 80,839 80,041 121,354 123,470 Minority interests (0) 0 0 0 0 Shareholders' equity 108 80,839 80,041 121,354 123,470 CASH FLOW Op Cash Flow before WC and tax 46 2,943 (1,406) 2,700 3,339 Working capital (28) (20) 650 5,250 (87) Exceptional & other 0 (4,952) (1,268) (5,107) (3,694) Tax 0 0 0 0 0 Net operating cash flow 18 (2,029) (2,024) 2,843 (442) Capex (30) (27) (113) (82) (75) Acquisitions/disposals 0 (11,563) (20,939) (8,779) (10,664) Net interest 0 22 397 165 260 Equity financing (4) 67,230 (22) 38,750 0 Dividends 0 0 0 0 0 Other 0 (30,000) 20,000 (25,000) 25,000 Net Cash Flow (16) 23,633 (2,701) 7,897 14,079 Opening net debt/(cash) (54) (39) (23,633) (20,932) (28,829) FX 0 0 0 0 0 Other non-cash movements 0 (39) 0 0 0 Closing net debt/(cash) (39) (23,633) (20,932) (28,829) (42,908) Closing net debt/ (cash) inc short-term liquidity investments (not EIS) (39) (53,633) (30,932) (59,601) (49,435) Source: Mercia Technologies Mercia Technologies 4 December 2018 4

General disclaimer and copyright This report has been commissioned by Mercia Technologies and prepared and issued by Edison, in consideration of a fee payable by Mercia Technologies. Edison Investment Research standard fees are 49,500 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services. Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the Edison analyst at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note. No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors. Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest. Copyright: Copyright 2018 Edison Investment Research Limited (Edison). All rights reserved FTSE International Limited ( FTSE ) FTSE 2018. FTSE is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE s express written consent. Australia Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Myonlineadvisers Pty Ltd who holds an Australian Financial Services Licence (Number: 427484). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument. New Zealand The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are wholesale clients for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a personalised service and, to the extent that it contains any financial advice, is intended only as a class service provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. United Kingdom Neither this document and associated email (together, the "Communication") constitutes or form part of any offer for sale or subscription of, or solicitation of any offer to buy or subscribe for, any securities, nor shall it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever. Any decision to purchase shares in the Company in the proposed placing should be made solely on the basis of the information to be contained in the admission document to be published in connection therewith. This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document (nor will such persons be able to purchase shares in the placing). This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person. United States Neither this Communication nor any copy (physical or electronic) of it may be (i) taken or transmitted into the United States of America, (ii) distributed, directly or indirectly, in the United States of America or to any US person (within the meaning of regulations Regulation S made under the US Securities Act 1933, as amended), (iii) taken or transmitted into or distributed in Canada, Australia, the Republic of Ireland or the Republic of South Africa or to any resident thereof, except in compliance with applicable securities laws, (iv) taken or transmitted into or distributed in Japan or to any resident thereof for the purpose of solicitation or subscription or offer for sale of any securities or in the context where the distribution thereof may be construed as such solicitation or offer, or (v) or taken or transmitted into any EEA state other than the United Kingdom. Any failure to comply with these restrictions may constitute a violation of the securities laws or the laws of any such jurisdiction. The distribution of this Communication in or into other jurisdictions may be restricted by law and the persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Frankfurt +49 (0)69 78 8076 960 Mercia Schumannstrasse Technologies 34b 4 December 280 High 2018 Holborn 295 Madison Avenue, 18th Floor Level 4, Office 1205 5 60325 Frankfurt Germany London +44 (0)20 3077 5700 London, WC1V 7EE United Kingdom New York +1 646 653 7026 10017, New York US Sydney +61 (0)2 8249 8342 95 Pitt Street, Sydney NSW 2000, Australia